Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

PGEN

Precigen Inc

May 15 • 04:00PM ET

1.44

Dollar change +0.07
Percentage change 5.11	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN IBB SCHA VTWO IWC SMLF CNCR

Index	RUT	P/E	-	EPS (ttm)	-0.39	Insider Own	48.96%	Shs Outstand	248.92M	Perf Week	8.27%
Market Cap	363.48M	Forward P/E	-	EPS next Y	-0.27	Insider Trans	0.00%	Shs Float	128.82M	Perf Month	5.88%
Income	-96.91M	PEG	-	EPS next Q	-0.09	Inst Own	29.89%	Short Float	11.81%	Perf Quarter	2.86%
Sales	5.44M	P/S	66.82	EPS this Y	10.26%	Inst Trans	-6.78%	Short Ratio	16.13	Perf Half Y	61.78%
Book/sh	0.39	P/B	3.71	EPS next Y	22.29%	ROA	-51.49%	Short Interest	15.21M	Perf Year	19.01%
Cash/sh	0.18	P/C	8.12	EPS next 5Y	2.40%	ROE	-68.94%	52W Range	0.84 - 1.88	Perf YTD	7.46%
Dividend Est.	-	P/FCF	-	EPS past 5Y	36.94%	ROI	-94.63%	52W High	-23.40%	Beta	1.88
Dividend TTM	-	Quick Ratio	1.72	Sales past 5Y	-20.14%	Gross Margin	-71.88%	52W Low	72.37%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	1.72	EPS Y/Y TTM	-20.13%	Oper. Margin	-1428.50%	RSI (14)	55.79	Volatility	7.38% 6.05%
Employees	202	Debt/Eq	0.07	Sales Y/Y TTM	-76.60%	Profit Margin	-1781.72%	Recom	1.80	Target Price	9.00
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	3.74%	Payout	-	Rel Volume	0.76	Prev Close	1.37
Sales Surprise	-28.04%	EPS Surprise	-13.64%	Sales Q/Q	-42.46%	Earnings	May 14 AMC	Avg Volume	943.21K	Price	1.44
SMA20	5.34%	SMA50	1.08%	SMA200	6.03%	Trades		Volume	714,755	Change	5.11%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-22-24	Downgrade	JP Morgan	Neutral → Underweight
May-23-23	Initiated	JP Morgan	Neutral
Nov-18-22	Initiated	Cantor Fitzgerald	Overweight	$7
Feb-25-21	Initiated	Stifel	Buy	$13
Feb-22-21	Initiated	Wells Fargo	Overweight	$14
Feb-18-21	Initiated	B. Riley Securities	Buy	$10
May-08-20	Initiated	H.C. Wainwright	Buy	$5

May-14-24 05:20PM	Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Precigen Reports First Quarter 2024 Financial Results and Business Updates (PR Newswire)
08:21AM	Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 04:05PM	Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting (PR Newswire)
Apr-24-24 10:20AM	Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting (PR Newswire)
09:00AM	Loading…
09:00AM	Actym Therapeutics Appoints Thomas Smart as CEO (PR Newswire)
Mar-28-24 04:05PM	Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th (PR Newswire)
Mar-27-24 08:20AM	Analysts on Wall Street Lower Ratings for These 10 Stocks (Insider Monkey)
Mar-20-24 10:07AM	Precigen, Inc. (NASDAQ:PGEN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-19-24 08:53PM	PGEN Stock Earnings: Precigen Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:31PM	Precigen Inc (PGEN) Reports Full Year 2023 Financial Results (GuruFocus.com)
04:05PM	Precigen Reports Full Year 2023 Financial Results and Business Updates (PR Newswire)
Mar-12-24 04:05PM	Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis (PR Newswire)
Mar-05-24 04:05PM	Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th (PR Newswire)
Feb-06-24 04:05PM	Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (PR Newswire)
08:05AM	Loading…
Jan-16-24 08:05AM	Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission (PR Newswire)
Jan-08-24 08:30AM	Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire) +8.53%
Jan-02-24 12:40PM	Hedge Fund and Insider Trading News: David Einhorn, Bill Ackman, D. E. Shaw, Steve Cohen, Rob Citrone, Saba Capital, HighPeak Energy, Inc (HPK), Precigen Inc (PGEN), and More (Insider Monkey) +5.22%
Dec-18-23 04:05PM	Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire) -5.74%
Nov-29-23 04:05PM	Precigen to Participate in the JMP Securities Hematology and Oncology Summit (PR Newswire)
Nov-09-23 04:55PM	Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs (PR Newswire)
Nov-07-23 04:05PM	Precigen to Participate in the Stifel 2023 Healthcare Conference (PR Newswire) +12.93%
Sep-19-23 04:05PM	Precigen to Participate in Upcoming Leading Investor and Industry Conferences (PR Newswire) -8.33%
Aug-09-23 08:00AM	Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025 (PR Newswire) +6.90%
07:05AM	Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval (PR Newswire)
Aug-03-23 04:05PM	Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th (PR Newswire) -6.67%
Jun-20-23 07:30AM	Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis (PR Newswire)
Jun-05-23 04:05PM	Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients (PR Newswire)
Jun-03-23 12:00PM	Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers (PR Newswire)
May-31-23 08:05AM	Precigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer (PR Newswire)
08:00AM	Loading…
May-10-23 08:00AM	Precigen Reports First Quarter 2023 Financial Results and Business Updates (PR Newswire)
May-03-23 08:30AM	Precigen to Announce First Quarter 2023 Financial Results on May 10th (PR Newswire) +8.85%
Apr-26-23 04:05PM	Precigen to Present Latest Clinical Advancements for PRGN-3005 UltraCAR-T® and PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy at the 2023 ASCO Annual Meeting (PR Newswire)
Apr-17-23 09:01AM	Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T® with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023 (PR Newswire) +10.48%
Apr-03-23 04:30PM	Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T® (PR Newswire) +5.66%
Mar-29-23 08:05AM	Precigen Announces Further Advancement of UltraCAR-T® Platform with First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors (PR Newswire) +15.44%
Mar-28-23 08:05AM	Precigen to Participate in a Virtual Fireside Chat at Cantor's "The Future of Oncology" Virtual Symposium (PR Newswire)
Mar-06-23 04:05PM	Precigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates (PR Newswire)
Feb-07-23 08:00AM	Precigen Is Pioneering a Nonsurgical Treatment for a Debilitating Respiratory Disease; Positive Data Released on Recurrent Respiratory Papillomatosis Showed a 50% Complete Response (News Direct)
Jan-30-23 02:34PM	Germantown's Precigen raises $75M to advance treatments for rare diseases (American City Business Journals)
Jan-27-23 04:05PM	Precigen Announces Closing of Public Offering of Common Stock (PR Newswire)
Jan-24-23 10:40PM	Precigen Announces Pricing of $75.0 Million Public Offering of Common Stock (PR Newswire)
04:05PM	Precigen Announces Proposed $75.0 Million Public Offering of Common Stock (PR Newswire)
04:01PM	Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (PR Newswire)
Jan-11-23 06:45PM	Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-04-23 04:05PM	Precigen to Host a Virtual R&D Event on January 24th to Share Safety and Efficacy Data from the Phase 1 Dose Escalation and Expansion Cohorts of PRGN-2012 AdenoVerse Immunotherapy in Recurrent Respiratory Papillomatosis (PR Newswire) +5.41%
Dec-27-22 08:00AM	Precigens Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy (News Direct) -9.29%
Dec-19-22 04:05PM	Precigen to Present at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire) -5.70%
Dec-12-22 07:01PM	Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients (PR Newswire)
Nov-16-22 05:07AM	Bullish: Analysts Just Made A Noticeable Upgrade To Their Precigen, Inc. (NASDAQ:PGEN) Forecasts (Simply Wall St.) -6.15%
Nov-09-22 04:05PM	Precigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs (PR Newswire) -8.13%
Nov-02-22 04:30PM	Precigen to Announce Third Quarter 2022 Financial Results on November 9th (PR Newswire)
Sep-21-22 04:30PM	Precigen Names Rutul R. Shah Chief Operating Officer (PR Newswire) -13.81%
Sep-01-22 08:05AM	Precigen to Participate in the 2022 Wells Fargo Healthcare Conference (PR Newswire)
Aug-22-22 08:05AM	Precigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics (PR Newswire)
Aug-08-22 04:05PM	Precigen Reports Second Quarter and First Half 2022 Financial Results (PR Newswire)
Aug-05-22 08:36AM	Investors in Precigen (NASDAQ:PGEN) from five years ago are still down 89%, even after 32% gain this past week (Simply Wall St.)
Aug-01-22 04:05PM	Precigen to Announce Second Quarter and First Half 2022 Financial Results on August 8th (PR Newswire)
Jul-06-22 08:09AM	Reston audience measurement company comScore names its next CEO (American City Business Journals) -9.88%
Jul-05-22 08:05AM	Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics (PR Newswire) +14.89%
Jun-27-22 04:05PM	Precigen to Participate in the Stifel 2022 Virtual Cell Therapy Summit (PR Newswire)
May-17-22 04:05PM	Precigen to Participate in the 2022 H.C. Wainwright Global Investment Conference (PR Newswire)
May-14-22 08:15AM	Need To Know: Analysts Are Much More Bullish On Precigen, Inc. (NASDAQ:PGEN) Revenues (Simply Wall St.)
May-11-22 06:29AM	Earnings Update: Precigen, Inc. (NASDAQ:PGEN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts (Simply Wall St.) -7.75%
May-09-22 04:05PM	Precigen Reports First Quarter 2022 Financial Results and Business Updates (PR Newswire) -8.00%
May-02-22 03:00PM	Precigen, Inc. (PGEN) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) +5.26%
Apr-04-22 08:05AM	Precigen Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid Leukemia (PR Newswire) +11.45%
Apr-03-22 03:40PM	What Type Of Shareholders Make Up Precigen, Inc.'s (NASDAQ:PGEN) Share Registry? (Simply Wall St.)
Mar-01-22 08:00AM	Precigen Reports Fourth Quarter and Full Year 2021 Financial Results (PR Newswire)
Feb-02-22 10:10AM	Further weakness as Precigen (NASDAQ:PGEN) drops 10% this week, taking five-year losses to 88% (Simply Wall St.) -10.38%
Feb-01-22 09:38PM	AGF Investments LLC Buys Health Care Select Sector SPDR, Financial Select Sector SPDR, The ... (GuruFocus.com)
Jan-24-22 02:48PM	It's been a tough year so far on Wall Street. These D.C.-area companies have suffered the biggest hits. (American City Business Journals)
Jan-12-22 04:30PM	Precigen Provides Pipeline and Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-11-22 10:00AM	Here's Why Precigen, Inc. (PGEN) Could be Great Choice for a Bottom Fisher (Zacks)
Jan-05-22 04:05PM	Precigen to Present at the 40th Annual J.P. Morgan Healthcare Conference (PR Newswire) -10.47%
Dec-13-21 05:05PM	Precigen Announces Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T® in Relapsed or Refractory Acute Myeloid Leukemia (PR Newswire)
Dec-01-21 07:56AM	A US$64m market cap addition is just what Precigen, Inc. (NASDAQ:PGEN) insiders like to see after purchasing stock worth US$3.7m (Simply Wall St.)
Nov-24-21 08:38AM	Is the Options Market Predicting a Spike in Precigen (PGEN) Stock? (Zacks) +11.57%
Nov-10-21 04:05PM	Precigen to Present at the Stifel 2021 Virtual Healthcare Conference (PR Newswire) -10.72%
Nov-04-21 09:15AM	Precigen Achieves Significant Clinical Progress for UltraCAR-T® and AdenoVerse Therapies (PR Newswire)
Nov-01-21 03:01PM	Analysts Estimate Precigen, Inc. (PGEN) to Report a Decline in Earnings: What to Look Out for (Zacks) +6.42%
Oct-27-21 04:38PM	Precigen to Host R&D Update Virtual Event on November 4th to Share Clinical Developments (PR Newswire)
Oct-26-21 08:05AM	Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for PRGN-3007 UltraCAR-T® in Advanced ROR1+ Hematological and Solid Tumors (PR Newswire)
Oct-12-21 08:05AM	Precigen Appoints Harry Thomasian Jr. as Chief Financial Officer (PR Newswire)
Oct-05-21 05:00AM	Here are Greater Washington's highest-paid public company CEOs (American City Business Journals)
Oct-04-21 08:34AM	Implied Volatility Surging for Precigen (PGEN) Stock Options (Zacks)
Oct-01-21 08:05AM	Precigen ActoBio Announces Additional Positive Interim Data from Phase 1b/2a Study of AG019 ActoBiotics, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes (PR Newswire)
Sep-21-21 10:55AM	What Kind Of Investors Own Most Of Precigen, Inc. (NASDAQ:PGEN)? (Simply Wall St.)
Sep-01-21 08:05AM	Precigen to Present at the 2021 Wells Fargo Virtual Healthcare Conference and the H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire)
Aug-09-21 04:01PM	Precigen Reports Second Quarter and First Half 2021 Financial Results (PR Newswire)
Aug-02-21 04:05PM	Precigen to Announce Second Quarter and First Half 2021 Financial Results on August 9th (PR Newswire)
03:01PM	Earnings Preview: Precigen, Inc. (PGEN) Q2 Earnings Expected to Decline (Zacks)
Jun-23-21 05:12AM	If You Had Bought Precigen's (NASDAQ:PGEN) Shares Five Years Ago You Would Be Down 75% (Simply Wall St.)
Jun-10-21 05:05PM	Precigen ActoBio Announces Positive Topline Results from Phase 1b/2a Study of AG019 ActoBiotics, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes (PR Newswire)
04:05PM	Precigen to Present at the JMP Securities Life Sciences Conference (PR Newswire)
May-10-21 04:30PM	Precigen Reports First Quarter 2021 Financial Results (PR Newswire)
Apr-28-21 12:33PM	Precigen, Inc. (PGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Mar-30-21 04:05PM	Precigen Announces Departure of Chief Financial Officer (PR Newswire)
Mar-25-21 05:46AM	How Much Of Precigen, Inc. (NASDAQ:PGEN) Do Insiders Own? (Simply Wall St.)
Mar-23-21 08:05AM	Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP) (PR Newswire) -5.85%

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KIRK RANDAL J	Director	Mar 09 '24	Option Exercise	0.00	213,675	0	32,051,461	Mar 12 05:36 PM
KIRK RANDAL J	Director	Dec 28 '23	Buy	1.41	96,686	136,327	1,096,686	Dec 29 07:30 PM
KINDLER JEFFREY B	Director	Dec 28 '23	Sale	1.41	96,686	136,327	238,275	Dec 29 07:19 PM
MITCHELL DEAN J	Director	Sep 22 '23	Buy	1.41	25,000	35,250	356,836	Sep 25 04:02 PM
Sabzevari Helen	President and CEO	Aug 25 '23	Sale	1.53	76,969	117,763	1,560,004	Aug 25 07:04 PM
Lehr Donald P.	Chief Legal Officer	Aug 24 '23	Sale	1.64	10,947	17,953	428,916	Aug 25 07:03 PM
Thomasian Harry Jr.	Chief Financial Officer	Aug 24 '23	Sale	1.64	9,045	14,834	161,051	Aug 25 06:59 PM
Perez Jeffrey Thomas	SVP, IP Affairs	Aug 24 '23	Sale	1.64	8,891	14,581	458,903	Aug 25 07:00 PM
Shah Rutul R	Chief Operating Officer	Aug 24 '23	Sale	1.64	5,388	8,836	133,474	Aug 25 07:01 PM
Sabzevari Helen	President and CEO	Aug 18 '23	Sale	1.66	55,855	92,719	1,495,386	Aug 18 09:06 PM
Lehr Donald P.	Chief Legal Officer	Aug 17 '23	Sale	1.55	10,762	16,681	418,153	Aug 18 09:13 PM
Thomasian Harry Jr.	Chief Financial Officer	Aug 17 '23	Sale	1.55	8,893	13,784	152,162	Aug 18 09:15 PM
Perez Jeffrey Thomas	SVP, IP Affairs	Aug 17 '23	Sale	1.55	8,741	13,549	448,916	Aug 18 09:18 PM
Shah Rutul R	Chief Operating Officer	Aug 17 '23	Sale	1.55	5,298	8,212	123,382	Aug 18 09:09 PM
KIRK RANDAL J	Director	Aug 16 '23	Buy	1.51	119,411	180,311	31,837,786	Aug 17 08:19 AM
KIRK RANDAL J	Director	Aug 15 '23	Buy	1.52	380,589	577,301	31,718,375	Aug 17 08:19 AM
Hassan Fred	Director	Aug 14 '23	Buy	1.75	570,345	998,104	878,942	Aug 16 04:31 PM
Frank Steven	Director	Aug 14 '23	Buy	1.72	400,000	688,000	882,358	Aug 15 04:18 PM
Sabzevari Helen	President and CEO	Aug 11 '23	Sale	1.44	41,436	59,668	1,409,654	Aug 11 07:24 PM
Lehr Donald P.	Chief Legal Officer	Aug 10 '23	Sale	1.21	11,026	13,341	407,205	Aug 11 07:28 PM
Perez Jeffrey Thomas	SVP, IP Affairs	Aug 10 '23	Sale	1.21	8,956	10,837	438,779	Aug 11 07:26 PM
Thomasian Harry Jr.	Chief Financial Officer	Aug 10 '23	Sale	1.21	6,852	8,291	143,121	Aug 11 07:27 PM
Shah Rutul R	Chief Operating Officer	Aug 10 '23	Sale	1.21	5,429	6,569	113,200	Aug 11 07:29 PM
Sabzevari Helen	President and CEO	Aug 04 '23	Sale	1.10	52,870	58,157	1,309,503	Aug 04 07:05 PM
Lehr Donald P.	Chief Legal Officer	Aug 03 '23	Sale	1.20	10,821	12,985	396,521	Aug 04 07:09 PM
Perez Jeffrey Thomas	SVP, IP Affairs	Aug 03 '23	Sale	1.20	8,789	10,547	428,857	Aug 04 07:10 PM
Thomasian Harry Jr.	Chief Financial Officer	Aug 03 '23	Sale	1.20	6,724	8,069	132,039	Aug 04 07:08 PM
Shah Rutul R	Chief Operating Officer	Aug 03 '23	Sale	1.20	5,328	6,394	103,149	Aug 04 07:06 PM

Open in Screener

PRAX

Praxis Precision Medicines Inc

May 15 • 04:00PM ET

44.00

Dollar change -1.90
Percentage change -4.14	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF DWAS IWC PTH ITOT DFAC AVSC DFUS AVUS

Index	-	P/E	-	EPS (ttm)	-15.92	Insider Own	4.72%	Shs Outstand	17.11M	Perf Week	-13.30%
Market Cap	752.84M	Forward P/E	-	EPS next Y	-9.49	Insider Trans	0.00%	Shs Float	16.30M	Perf Month	-16.05%
Income	-125.38M	PEG	-	EPS next Q	-2.33	Inst Own	51.83%	Short Float	5.06%	Perf Quarter	4.04%
Sales	2.19M	P/S	343.76	EPS this Y	47.68%	Inst Trans	-5.98%	Short Ratio	3.77	Perf Half Y	237.16%
Book/sh	17.32	P/B	2.54	EPS next Y	2.97%	ROA	-71.89%	Short Interest	0.82M	Perf Year	171.60%
Cash/sh	12.12	P/C	3.63	EPS next 5Y	-14.60%	ROE	-85.25%	52W Range	12.45 - 67.21	Perf YTD	97.49%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-10.28%	ROI	-54.33%	52W High	-34.53%	Beta	2.81
Dividend TTM	-	Quick Ratio	11.27	Sales past 5Y	0.00%	Gross Margin	61.00%	52W Low	253.41%	ATR (14)	3.57
Dividend Ex-Date	-	Current Ratio	11.27	EPS Y/Y TTM	72.46%	Oper. Margin	-5930.20%	RSI (14)	34.17	Volatility	7.02% 7.07%
Employees	82	Debt/Eq	0.01	Sales Y/Y TTM	221.38%	Profit Margin	-5711.85%	Recom	1.43	Target Price	135.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	73.11%	Payout	-	Rel Volume	3.21	Prev Close	45.90
Sales Surprise	-78.05%	EPS Surprise	-36.35%	Sales Q/Q	-36.90%	Earnings	May 13 BMO	Avg Volume	218.92K	Price	44.00
SMA20	-13.86%	SMA50	-17.29%	SMA200	37.43%	Trades		Volume	702,980	Change	-4.14%

Date	Action	Analyst	Rating Change	Price Target Change
May-01-24	Initiated	Robert W. Baird	Outperform	$117
Sep-19-23	Initiated	Truist	Buy	$10
Jun-06-22	Downgrade	Wedbush	Outperform → Neutral	$4
Dec-16-21	Initiated	H.C. Wainwright	Buy	$48
Aug-26-21	Initiated	BofA Securities	Buy	$28
Apr-26-21	Initiated	William Blair	Outperform
Nov-11-20	Initiated	Wedbush	Outperform	$40
Nov-10-20	Initiated	Piper Sandler	Overweight	$65
Nov-10-20	Initiated	Evercore ISI	Outperform	$55
Nov-10-20	Initiated	Cowen	Outperform

May-13-24 11:53AM	PRAX Stock Earnings: Praxis Precision Medicine Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -7.36%
07:00AM	Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-10-24 08:00AM	Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024 (GlobeNewswire)
May-03-24 04:45PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-24 09:55AM	Wall Street Analysts See a 144.74% Upside in Praxis Precision Medicines (PRAX): Can the Stock Really Move This High? (Zacks)
07:10AM	Loading…
May-01-24 07:10AM	Baird Initiates Praxis Precision Medicines With Outperform Rating, $117 Price Target (MT Newswires)
Apr-12-24 08:00AM	Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting (GlobeNewswire)
Apr-11-24 12:00PM	Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why (Zacks) +6.43%
Apr-05-24 09:00AM	Praxis Precision Medicines to Participate in Upcoming April Conferences (GlobeNewswire)
Apr-02-24 05:00PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.17%
Mar-29-24 06:23AM	Health Care Roundup: Market Talk (The Wall Street Journal)
Mar-28-24 12:20AM	Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering (GlobeNewswire)
Mar-27-24 04:01PM	Praxis Precision Medicines, Inc. Announces Proposed Public Offering (GlobeNewswire)
10:53AM	Praxis (PRAX) Surges on Positive Epilepsy Study Results (Zacks)
Mar-26-24 04:14PM	Top 1% Biotech, Praxis, Releases 'Fireworks' And Catapults To Year-High (Investor's Business Daily) +23.13%
09:21AM	Loading…
09:21AM	Praxis, A Top 1% Stock, Soars To Year-High After Epilepsy Treatment Scores Big (Investor's Business Daily)
06:30AM	Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients (GlobeNewswire)
Mar-25-24 04:01PM	Praxis Precision Medicines to Host PRAX-628 Program Update (GlobeNewswire) -6.26%
Mar-08-24 12:00PM	What Makes Praxis Precision Medicines, Inc. (PRAX) a Strong Momentum Stock: Buy Now? (Zacks)
Mar-07-24 01:31PM	Praxis Precision Medicines Inc (PRAX) Reports Full-Year 2023 Financial Results and Corporate Updates (GuruFocus.com)
Mar-06-24 09:55AM	Wall Street Analysts Think Praxis Precision Medicines, Inc. (PRAX) Could Surge 134.35%: Read This Before Placing a Bet (Zacks) +8.35%
Mar-05-24 08:10AM	Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Mar-01-24 08:00AM	Praxis Precision Medicines to Participate in TD Cowen's 44th Annual Health Care Conference (GlobeNewswire) +5.90%
Feb-02-24 04:00PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-11-24 07:30AM	Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering (GlobeNewswire) +11.66%
Jan-10-24 04:19PM	Praxis Precision Medicines, Inc. Announces Proposed Public Offering (GlobeNewswire)
Jan-09-24 04:57PM	Praxis Precision Medicines, Inc. (PRAX) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +24.96%
Jan-08-24 08:00AM	Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio (GlobeNewswire) +24.85%
Jan-05-24 09:55AM	Praxis Precision Medicines, Inc. (PRAX) Just Flashed Golden Cross Signal: Do You Buy? (Zacks) -7.12%
08:00AM	Loading…
08:00AM	Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China (GlobeNewswire)
Nov-30-23 09:55AM	Wall Street Analysts Believe Praxis Precision Medicines, Inc. (PRAX) Could Rally 494.95%: Here's is How to Trade (Zacks)
Nov-28-23 07:00AM	Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings (GlobeNewswire) -9.09%
Nov-21-23 04:00PM	Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire) -13.01%
Nov-16-23 08:00AM	Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies (GlobeNewswire)
Nov-14-23 09:35AM	Praxis Precision Medicines, Inc. (PRAX) Loses -32.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +5.48%
Nov-07-23 08:00AM	Praxis Precision Medicines Inc (PRAX) Reports Q3 2023 Financial Results (GuruFocus.com) +6.51%
07:00AM	Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-02-23 08:00AM	Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium (GlobeNewswire) +5.41%
Oct-02-23 01:17PM	Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day (GlobeNewswire)
Sep-27-23 04:15PM	Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023 (GlobeNewswire)
Sep-07-23 08:00AM	Praxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) +5.11%
Aug-31-23 08:00AM	Praxis Precision Medicines to Present Data from Epilepsy Portfolio at the 35th International Epilepsy Congress (GlobeNewswire) +5.76%
Aug-28-23 07:00AM	Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress (GlobeNewswire)
Aug-17-23 10:04AM	Billionaire Steve Cohen Loads Up on These 2 Strong Buy Penny Stocks Heres Why Wall Street Sees Over 500% Upside Potential (TipRanks) +18.58%
Aug-11-23 07:00AM	The past year for Praxis Precision Medicines (NASDAQ:PRAX) investors has not been profitable (Simply Wall St.)
Aug-09-23 07:00AM	Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-08-23 07:00AM	Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide (GlobeNewswire)
Aug-07-23 07:00AM	Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study (GlobeNewswire)
Aug-03-23 04:12PM	Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jul-14-23 10:20AM	Following a 63% decline over last year, recent gains may please Praxis Precision Medicines, Inc. (NASDAQ:PRAX) institutional owners (Simply Wall St.) -13.53%
Jun-22-23 07:00AM	Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities (GlobeNewswire)
Jun-17-23 09:41AM	Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth? (Simply Wall St.)
Jun-15-23 11:58PM	Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering (GlobeNewswire) +6.47%
04:01PM	Praxis Precision Medicines, Inc. Announces Proposed Public Offering (GlobeNewswire)
Jun-09-23 07:00AM	Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA (GlobeNewswire)
Jun-02-23 09:00AM	Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire) +15.15%
May-11-23 01:12PM	Praxis Precision Medicines Says PRAX-628 Can Potentially Be The Best-In-Class Treatment For Focal Epilepsy (Benzinga)
07:30AM	Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
06:55AM	Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile (GlobeNewswire)
May-07-23 09:22AM	Pleasing Signs As A Number Of Insiders Buy Praxis Precision Medicines Stock \ (Simply Wall St.)
Apr-19-23 08:00AM	Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting (GlobeNewswire)
Apr-17-23 08:00AM	Praxis Precision Medicines Announces Upcoming Ulixacaltamide Presentations & Events (GlobeNewswire) +6.00%
Apr-06-23 09:00AM	Praxis Precision Medicines to Present at 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-03-23 04:05PM	Praxis Precision Medicines to Present at Upcoming Investor Conferences (GlobeNewswire) -65.87%
11:05AM	Despite Trial Failure Praxis Still Seeks Advancing Essential Tremor Program Into Phase 3 Study (Benzinga)
07:30AM	Praxis Precision Medicines Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3 (GlobeNewswire)
Feb-07-23 08:00AM	Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Dec-13-22 04:01PM	Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration (GlobeNewswire)
Nov-28-22 04:05PM	Praxis Precision Medicines to Present at the American Epilepsy Society 2022 Annual Meeting (GlobeNewswire)
08:00AM	Praxis Precision Medicines to Advance PRAX-562 Phase 2 Study in Pediatric Patients with Developmental and Epileptic Encephalopathies (GlobeNewswire)
Nov-09-22 04:01PM	Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire) -7.08%
05:42AM	Positive week for Praxis Precision Medicines, Inc. (NASDAQ:PRAX) institutional investors who lost 89% over the past year (Simply Wall St.)
Nov-07-22 09:00AM	Praxis Precision Medicines to Present at Upcoming Investor Conferences (GlobeNewswire)
Sep-26-22 06:28AM	Praxis Precision Medicines (NASDAQ:PRAX) Will Have To Spend Its Cash Wisely (Simply Wall St.)
Sep-21-22 09:00AM	Praxis Precision Medicines to Present at Guggenheim Nantucket Therapeutics Conference (GlobeNewswire)
Sep-20-22 08:30AM	Invitaes Real-World Ciitizen Data Utilized in Praxis Precision Medicines PRAX-222 IND Filing (GlobeNewswire) +7.98%
Sep-07-22 04:05PM	Praxis Precision Medicines to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +9.31%
10:46AM	Praxis Precision Outlines Upcoming Plans For Pediatric Epilepsy Programs (Benzinga)
07:30AM	Praxis Precision Medicines Provides Updates on Clinical Stage Pediatric Epilepsy Programs (GlobeNewswire)
Aug-08-22 04:01PM	Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire) +19.82%
Aug-03-22 09:00AM	Praxis Precision Medicines to Present at 2022 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jul-11-22 02:20PM	Needham Previews Neurocrine's Upcoming Mid-Stage Data from Essential Tremor Study (Benzinga)
Jun-26-22 09:47AM	Insiders at Praxis Precision Medicines, Inc. (NASDAQ:PRAX) recouped some losses this week after buying this year, still down US$156k (Simply Wall St.)
Jun-07-22 11:30AM	Praxis (PRAX) Tanks on Negative Data From Depression Study (Zacks)
Jun-06-22 08:39AM	Praxis Precision Posts Disappointing Data From Depression Study (Benzinga) -78.11%
07:45AM	Praxis Precision Medicines Reports Negative Results from PRAX-114 Phase 2/3 Monotherapy Aria Study in Patients with Major Depressive Disorder (GlobeNewswire)
May-23-22 09:00AM	Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone (GlobeNewswire) -8.31%
May-13-22 12:54PM	Analysts See an Attractive Entry Point in These 3 Stocks (TipRanks) +14.11%
May-11-22 09:00AM	Praxis Precision Medicines to Present at Upcoming Investor Conferences (GlobeNewswire)
May-10-22 08:22AM	Praxis' PRAX-944 Shows Promising Action In Essential Tremor Patients (Benzinga) +24.63%
May-09-22 04:01PM	Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Study in Essential Tremor Patients (GlobeNewswire) -8.54%
04:01PM	Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-04-22 09:00AM	Praxis Precision Medicines to Present at BofA Securities 2022 Healthcare Conference (GlobeNewswire)
May-02-22 04:15PM	Praxis Precision Medicines to Provide Corporate Update and Report First Quarter 2022 Financial Results on Monday, May 9, 2022 (GlobeNewswire) +8.64%
Apr-27-22 08:25AM	Praxis Precision Medicines Showcases Largest Targeted Epilepsy Portfolio in Industry at 2022 Epilepsy Day (GlobeNewswire)
Apr-18-22 03:08PM	Is Praxis Precision Medicines (NASDAQ:PRAX) In A Good Position To Invest In Growth? (Simply Wall St.)
Apr-13-22 08:00AM	Praxis Precision Medicines to Host Epilepsy Day on April 27, 2022 (GlobeNewswire)
Apr-01-22 09:00AM	Praxis Precision Medicines to Present Data from PRAX-944 for Essential Tremor at 2022 American Academy of Neurology Annual Meeting (GlobeNewswire)
Mar-21-22 09:00AM	Praxis Precision Medicines to Present at Stifels 4th Annual CNS Day (GlobeNewswire) -7.29%

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. It is a targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DeSimone Jill	Director	Oct 05 '23	Buy	1.75	14,500	25,375	14,500	Oct 10 07:41 AM
Souza Marcio	Chief Executive Officer	Jun 27 '23	Buy	1.06	10,000	10,587	45,002	Jun 27 07:52 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

PGEN

Precigen Inc

PRAX

Praxis Precision Medicines Inc

Upgrade your FINVIZ experience